Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company, has entered into a worldwide agreement with Dr. Reddy’s Laboratories Limited, a global pharmaceutical leader, marking a significant advancement in the treatment of neurodegenerative diseases. This collaboration focuses on the development of COYA 302, a dual biologic designed to combat neuroinflammation and treat various neurodegenerative conditions. […]
Dr. Reddy’s Laboratories, an Indian pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for a comprehensive review of its proposed biosimilar rituximab candidate, DRL_RI. This news comes on the heels of similar acceptance from the European Medicines Agency (EMA) and the United Kingdom’s Medicines and […]
Dr. Reddy’s Laboratories, an Indian pharmaceutical company, announced a significant milestone as its tocilizumab biosimilar candidate, DRL_TC, successfully met primary and secondary endpoints in a phase 1 clinical trial. The early-stage study, titled ‘A Phase I, Double Blind, Randomized, Parallel-group, Single dose, Three arm, Comparative Pharmacokinetic and Pharmacodynamic Study of Dr. Reddy’s Laboratories’ Tocilizumab (DRL_TC), […]
